Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.

<h4>Background</h4>Neuropsychiatric systemic lupus erythematosus (NPSLE) is a common and potentially fatal manifestation of SLE. Antiphospholipid antibodies (aPL) such as lupus anticoagulant (LA), anticardiolipin (aCL) and antibodies to β2glycoprotein I (anti-β2GPI), the most important a...

Full description

Bibliographic Details
Main Authors: Tomasz Hawro, Andrzej Bogucki, Maria Krupińska-Kun, Marcus Maurer, Anna Woźniacka
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0119911
id doaj-847f16d540124c6cbca2a8fdfed7ffc5
record_format Article
spelling doaj-847f16d540124c6cbca2a8fdfed7ffc52021-03-04T08:31:19ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01103e011991110.1371/journal.pone.0119911Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.Tomasz HawroAndrzej BoguckiMaria Krupińska-KunMarcus MaurerAnna Woźniacka<h4>Background</h4>Neuropsychiatric systemic lupus erythematosus (NPSLE) is a common and potentially fatal manifestation of SLE. Antiphospholipid antibodies (aPL) such as lupus anticoagulant (LA), anticardiolipin (aCL) and antibodies to β2glycoprotein I (anti-β2GPI), the most important aPL antigen, are thought to play a role in some forms of NPSLE. As of yet, their specific roles in NPSLE manifestations remain to be elucidated.<h4>Methodology/principal findings</h4>57 SLE patients (53 women) were assessed for LA, aCL and anti-β2GPI twice, to determine persistent positivity. All patients were examined by neurology and psychiatry specialists. 69 healthy subjects were assessed as controls. NPSLE was diagnosed in 74% of patients. Headaches were the most prevalent manifestation of NPSLE (39%), followed by cerebrovascular disease (CVD) (23%), depressive disorders (19.0%), and seizures (14%). NPSLE and non-NPSLE patients showed comparable SLE activity and corticosteroid use. In 65% of patients neuropsychiatric manifestations preceded SLE diagnosis. aPL profiles of NPSLE patients and non-NPSLE patients were similar. Headaches and ischemic stroke were independently associated with anti-β2GPI-IgM (OR=5.6; p<0.05), and seizures were linked to anti-β2GPI-IgG (OR=11.3; p=0.01).<h4>Conclusions</h4>In SLE patients, neuropsychiatric manifestations occur frequently and early, often before the disease is diagnosed. Autoantibodies to β2GPI are linked to non-specific headaches, ischemic stroke and seizures, and show a better predictive value than aCL and LA. These findings may help to improve the diagnosis of NPSLE and should prompt further studies to characterize the role of anti-β2GPI in the pathogenesis of this condition.https://doi.org/10.1371/journal.pone.0119911
collection DOAJ
language English
format Article
sources DOAJ
author Tomasz Hawro
Andrzej Bogucki
Maria Krupińska-Kun
Marcus Maurer
Anna Woźniacka
spellingShingle Tomasz Hawro
Andrzej Bogucki
Maria Krupińska-Kun
Marcus Maurer
Anna Woźniacka
Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.
PLoS ONE
author_facet Tomasz Hawro
Andrzej Bogucki
Maria Krupińska-Kun
Marcus Maurer
Anna Woźniacka
author_sort Tomasz Hawro
title Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.
title_short Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.
title_full Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.
title_fullStr Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.
title_full_unstemmed Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus.
title_sort intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2gpi antibodies in patients with systemic lupus erythematosus.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description <h4>Background</h4>Neuropsychiatric systemic lupus erythematosus (NPSLE) is a common and potentially fatal manifestation of SLE. Antiphospholipid antibodies (aPL) such as lupus anticoagulant (LA), anticardiolipin (aCL) and antibodies to β2glycoprotein I (anti-β2GPI), the most important aPL antigen, are thought to play a role in some forms of NPSLE. As of yet, their specific roles in NPSLE manifestations remain to be elucidated.<h4>Methodology/principal findings</h4>57 SLE patients (53 women) were assessed for LA, aCL and anti-β2GPI twice, to determine persistent positivity. All patients were examined by neurology and psychiatry specialists. 69 healthy subjects were assessed as controls. NPSLE was diagnosed in 74% of patients. Headaches were the most prevalent manifestation of NPSLE (39%), followed by cerebrovascular disease (CVD) (23%), depressive disorders (19.0%), and seizures (14%). NPSLE and non-NPSLE patients showed comparable SLE activity and corticosteroid use. In 65% of patients neuropsychiatric manifestations preceded SLE diagnosis. aPL profiles of NPSLE patients and non-NPSLE patients were similar. Headaches and ischemic stroke were independently associated with anti-β2GPI-IgM (OR=5.6; p<0.05), and seizures were linked to anti-β2GPI-IgG (OR=11.3; p=0.01).<h4>Conclusions</h4>In SLE patients, neuropsychiatric manifestations occur frequently and early, often before the disease is diagnosed. Autoantibodies to β2GPI are linked to non-specific headaches, ischemic stroke and seizures, and show a better predictive value than aCL and LA. These findings may help to improve the diagnosis of NPSLE and should prompt further studies to characterize the role of anti-β2GPI in the pathogenesis of this condition.
url https://doi.org/10.1371/journal.pone.0119911
work_keys_str_mv AT tomaszhawro intractableheadachesischemicstrokeandseizuresarelinkedtothepresenceofantib2gpiantibodiesinpatientswithsystemiclupuserythematosus
AT andrzejbogucki intractableheadachesischemicstrokeandseizuresarelinkedtothepresenceofantib2gpiantibodiesinpatientswithsystemiclupuserythematosus
AT mariakrupinskakun intractableheadachesischemicstrokeandseizuresarelinkedtothepresenceofantib2gpiantibodiesinpatientswithsystemiclupuserythematosus
AT marcusmaurer intractableheadachesischemicstrokeandseizuresarelinkedtothepresenceofantib2gpiantibodiesinpatientswithsystemiclupuserythematosus
AT annawozniacka intractableheadachesischemicstrokeandseizuresarelinkedtothepresenceofantib2gpiantibodiesinpatientswithsystemiclupuserythematosus
_version_ 1714807794641666048